Immunomodulatory and Immunsuppressive Drugs in Dermatology — Ümit Türsen

Recently dermatologists have witnessed a revolution in our therapeutic armamentarium with the development of several novel immunomodulators Although psoriasis remains the only condition in dermatology for which the use of immunomodulators has been approved by the Food and Drug Administration these drugs have the potential to signifi cantly impact the treatment of several infl ammatory conditions in dermatology Th is books includes a review of the mechanism of action dosing and side eff ect profi le as well as a review of the current literature on immunomudulatory and immunosuppressive drugs in dermatology and also off label uses of the CD20 positive B cell antagonist rituximab the IgE antagonist omalizumab the tumor necrosis factor α antagonists infl iximab etanercept and adalimumab the pathogenic autoantibody antagonist IVIG the antirheumatic drug lefl unomide the T cell response modifi ers alefacept the toll like receptor 7 agonist topical imiquimod the oral hypoglycaemic agent metformin the phosphodieasterase 4 inhibitor Apremilast and also the new other immunomodulatory drugs and herbs